FIG. 1A



Lipid
TM
N-Glyc
F1
574 aa
Fusion peptide
Fur 2
Fur 1
pep27
N-Glyc
F2
N glyc
Sp

FIG. 1B



Added Coiled-coil
N-Glyc
F1
514 aa
Fusion peptide
N-Glyc
F2
N glyc
Sp
Added Coiled-coil
N-Glyc
F1
central region of G protein
Fusion peptide
N-Glyc
F2
N glyc
Sp

FIG. 2

Study design for guinea pig experiment performed in Example 1




FIG. 3

Protection of guinea pig pups from RSV challenge performed in Example 1





FIG. 4

Time-course of neutralizing antibody response post-priming (prior to vaccination) in guinea pig model in Example 1



	D0	D14	D28	D42-D47	D56	D70-D75
Priming Day 0 (no vaccine)	8	588	769	615	979	733
Priming Day 0 (10 wks pre-vacc)	8	532	534	463	673	623
Priming Day 28 (6 wks pre-vacc)	8	8	8	516	628	774

FIG. 5A



Neutra titer (ED_{60})
Geomean +/- 95%CI
1000
100
10
p < 0.005
262
95
5
4
PreF + AlOH
PreF-PA + AlOH
PreF-PA
PA + AlOH

FIG. 5B



RSV titre in lung ($TCID_{50}$/g)
Geomean +/- 95% CI
1000000
100000
10000
1000
P < 0.001 for all groups
669
558
10383
105344
PreF + AlOH
PreF + PA + AlOH
PreF + PA
PA + AlOH (Cuti)
Limit of detection = 500 $TCID_{50}$/g

FIG. 6A



antibody STD titers (EU/ml)(GMT +/- IC95)
24000
21000
18000
15000
12000
9000
6000
3000
0
DTPa
Standalone Pa
Pa-RSV combination
6308
8120
5129
8867
5925
6627
16925
15308
12669
FHA
PT
PRN

FIG. 6B



Mean log 10CFU/lung
8
7
6
5
4
3
2
1
0
Negative control
DTPa
Standalone Pa
RSV (Pre-F2)
Pa-RSV combination
0+2h
2
5
8
Days after challenge

FIG. 7A (dams)




FIG. 7B (pups)




FIG. 8

Protection of guinea pig pups from RSV challenge performed in Example 4

